| pubmed-article:8158579 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8158579 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8158579 | lifeskim:mentions | umls-concept:C1519658 | lld:lifeskim |
| pubmed-article:8158579 | lifeskim:mentions | umls-concept:C0037956 | lld:lifeskim |
| pubmed-article:8158579 | lifeskim:mentions | umls-concept:C0005456 | lld:lifeskim |
| pubmed-article:8158579 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8158579 | pubmed:dateCreated | 1994-5-19 | lld:pubmed |
| pubmed-article:8158579 | pubmed:abstractText | We previously reported that dopamine (DA) inhibited the release of human placental lactogen (hPL) from human placental cells. We also demonstrated the presence of D2-dopamine receptors in membrane preparations of human term placenta. The aim of the present study was to characterize these D2 receptors on freshly isolated human trophoblastic cells. The binding of [3H]-spiperone to these cells showed a curvilinear Scatchard plot suggesting the presence of two classes of binding sites (Kd1 = 1.26nM; Kd2 = 44.3nM). Competition experiments showed the following inhibitory binding potencies: serotonin-2 (5-HT2) > or = D2 >>> alpha-adrenergic, beta-adrenergic, D1-dopamine, thus suggesting the presence of 5-HT2 binding sites. We have examined this possibility by blocking [3H]-spiperone binding to 5-HT2 receptors in the presence of 50nM ketanserin, a selective antagonist of 5-HT2 sites. Under this condition, the linear Scatchard plot obtained suggested a single population of homogeneous binding sites for [3H]-spiperone with a Kd of 0.55nM. To further characterize placental D2 receptors we conducted binding experiments with [3H]-raclopride, an more selective D2 antagonist. The linear Scatchard plot obtained with this ligand suggested one class of binding sites for [3H]-raclopride (Kd = 6nM) with the following inhibitory potencies: D2 >>> beta-adrenergic >> 5-HT2, D1, alpha-adrenergic. These results suggest an important paracrine function for DA in human placenta and show for the first time that [3H]-spiperone binds putative 5-HT2 receptors in human placenta. | lld:pubmed |
| pubmed-article:8158579 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8158579 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8158579 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8158579 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8158579 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8158579 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8158579 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8158579 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8158579 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8158579 | pubmed:issn | 0197-5110 | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:LehouxJ GJG | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:PetitAA | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:BélisleSS | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:VaillancourtC... | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:BellabarbaDD | lld:pubmed |
| pubmed-article:8158579 | pubmed:author | pubmed-author:Gallo-PayetNN | lld:pubmed |
| pubmed-article:8158579 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8158579 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8158579 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8158579 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8158579 | pubmed:pagination | 11-22 | lld:pubmed |
| pubmed-article:8158579 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:meshHeading | pubmed-meshheading:8158579-... | lld:pubmed |
| pubmed-article:8158579 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8158579 | pubmed:articleTitle | Labelling of D2-dopaminergic and 5-HT2-serotonergic binding sites in human trophoblastic cells using [3H]-spiperone. | lld:pubmed |
| pubmed-article:8158579 | pubmed:affiliation | Departement of Obstetrics and Gynecology, Faculty of Medecine, University of Montreal, Quebec, Canada. | lld:pubmed |
| pubmed-article:8158579 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8158579 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:8158579 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
